drugset / Trial / NCT02505984

Preventing Postpartum Depression With Intranasal Oxytocin

NCT02505984

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to test a new treatment for preventing childbirth-related mental illness in postpartum mothers. The treatment is aimed at enhancing maternal bonding, reducing postpartum depression (PPD) and anxiety in mothers at risk, and promoting child development. To this end, the investigators will test the clinical utility of intranasal (IN) oxytocin (OXT) administered to mothers during the first postpartum days.

Timeline

Start
2016-01
Primary completion
2023-05
Completion
2023-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxytocin Peptide 48 iu Intranasal